Contract Research Organizations (CROs) to Watch in 2021
The contract research organization (CRO) industry is constantly evolving to meet the needs of the pharmaceutical and biotech companies that they serve. As we move into 2021, there are a few CROs that we are keeping our eye on. These CROs are leading the charge in innovation and are poised to make a big impact in the coming year.1. PRA Health Sciences
PRA Health Sciences is a global CRO that offers a comprehensive suite of services to support clinical development. In 2020, they acquired Omnicare Clinical Research, a leading provider of early phase clinical development services. This acquisition strengthens PRA’s position as a full-service CRO and gives them a greater presence in the early phase space. In addition to their clinical development services, PRA also offers data management, biostatistics, and regulatory affairs services.
2. ICON
ICON is a global CRO that specializes in clinical development, commercialization, and data solutions. They have a strong focus on patient-centered research and have developed several innovative solutions to support this. Their myPatient Portal is a patient engagement platform that allows patients to self-report data and stay engaged in their own care. They also have a mobile app, myICON, which allows patients to access their clinical trial data on their own devices. These patient-centric solutions are helping to improve clinical trial outcomes and make the research process more efficient.
3. Covance
Covance is a leading CRO that offers a comprehensive suite of drug development services. They have a strong focus on precision medicine and have developed several innovative solutions to support this. Their Oncospace platform is a cloud-based data management system that helps oncologists to identify the best treatment options for their patients. Their Clinical Genomics Lab is a state-of-the-art facility that uses next-generation sequencing to provide actionable insights for clinical trials. These precision medicine solutions are helping to improve patient outcomes and make the research process more efficient.
4. Charles River
Charles River is a global CRO that offers a comprehensive suite of services for early-stage drug development. They have a strong focus on innovation and
2. The CRO Landscape in 2021
In 2021, the contract research organization (CRO) landscape is expected to continue to evolve and change in response to the needs of the biopharmaceutical industry. Here is a sneak peek at some of the trends that are likely to shape the CRO landscape in the coming year:
1. An increase in the use of artificial intelligence (AI) and machine learning (ML) in drug development.
2. A continued focus on patient engagement and experience.
3. An increase in the use of real-world data (RWD) in drug development.
4. A continued move towards more virtual and decentralized clinical trials.
5. A continued increase in the use of data analytics in drug development.
6. A continued focus on quality and compliance.
7. An increase in the use of digital health technologies in clinical trials.
8. A continued focus on cost containment.
9. A continued focus on speed to market.
10. An increase in the use of personalized medicine in drug development.
3. What's Next for CROs?
The clinical research industry is constantly evolving and changing, and contract research organizations (CROs) are no exception. As the industry adapts to new challenges and opportunities, CROs are also changing and evolving to meet the needs of their clients. So, what's next for CROs?
One trend that is likely to continue is the trend towards more specialized CROs. As the clinical research industry becomes more complex, sponsors are increasingly looking for CROs that specialize in specific therapeutic areas or phases of clinical research. This trend is already underway, and we expect it to continue in the coming years.
Another trend that is likely to continue is the trend towards more virtual and remote clinical trials. With the advances in technology, it is now possible to conduct clinical trials with fewer on-site visits and more remote data collection. This trend is already underway, and we expect it to continue in the coming years.
Finally, we expect to see a continued trend towards more flexible and custom-tailored clinical research services. As the clinical research industry becomes more complex, sponsors are increasingly looking for CROs that can provide flexible and custom-tailored services to meet their specific needs. This trend is already underway, and we expect it to continue in the coming years Contract research organization list.
4. A Look Ahead: Key Trends in the CRO Industry
The CRO industry is constantly evolving, and it can be difficult to keep up with the latest trends. Here's a sneak peek at some of the key trends that are shaping the industry right now:
1. Increasing focus on patient engagement
There is a growing recognition that patients must be involved in every stage of the drug development process, from initial research all the way through to clinical trials. This is especially important in the field of rare diseases, where patients are often the only ones with first-hand knowledge of the condition.
2. Big data and real-world data
The ever-growing pool of data is becoming increasingly important in the CRO industry. Big data analytics is being used to identify patterns and trends that can help inform decision-making, and real-world data is being used to generate more accurate predictions of how drugs will perform in the real world.
3. Artificial intelligence
Artificial intelligence is starting to make its way into the CRO industry, with a number of companies exploring how it can be used to streamline and improve the drug development process. AI can be used for tasks such as target identification, lead optimization, and clinical trial design.
4. Emerging markets
The CRO industry is no longer just about developed markets such as the US and Europe. There is a growing demand for CRO services in emerging markets such as China, India, and Latin America. This is driven by the increasing number of clinical trials taking place in these regions, as well as the growing number of drug approvals.
Comments
Post a Comment